Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Replication-defective HIV as a vaccine candidate

F Y Tung1, C R Rinaldo, R C Montelaro

  • 1Department of Infectious Disease and Microbiology, University of Pittsburgh, Pennsylvania 15261, USA.

AIDS Research and Human Retroviruses
|October 9, 1998
PubMed
Summary

Researchers developed a replication-defective HIV vaccine candidate, pseudotyped with VSV-G, to improve safety for human trials. This novel vaccine elicits antibody immune responses while minimizing risks associated with live attenuated vaccines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A taxon-specific measurement of disruption in a multi-modal study of microbiomes and metabolomes reveals system-wide dysbiosis preceding HIV-1 infection.

Nature communications·2025
Same author

[EIAV (equine infectious anemia virus): to better understand the lentiviral pathogenesis].

Virologie (Montrouge, France)·2021
Same author

Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria.

Science advances·2020
Same author

Detection of IgG3 antibodies specific to the human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired infection.

Epidemiology and infection·2018
Same author

Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of Pseudomonas aeruginosa pneumonia.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

Linked in: immunologic membrane nanotube networks.

Journal of leukocyte biology·2016

Area of Science:

  • Virology
  • Immunology
  • Vaccine Development

Background:

  • Live attenuated vaccines from simian immunodeficiency virus (SIV) show promise for protective immunity.
  • Replication-competent viral vaccines pose safety concerns for human clinical trials.
  • Need for safer yet immunogenic vaccine strategies against lentiviruses.

Purpose of the Study:

  • To develop a safe and immunogenic live, attenuated vaccine candidate.
  • To create a replication-defective human immunodeficiency virus (HIV) vaccine.
  • To evaluate the immunogenicity of a novel VSV-G pseudotyped HIV vaccine.

Main Methods:

  • Constructed a replication-defective HIV by truncating the polymerase gene.
  • Pseudotyped the replication-defective HIV with vesicular stomatitis virus G protein (VSV-G).

Related Experiment Videos

  • Assessed the infectivity of the pseudotyped virus in human and simian cells.
  • Detected antibody immune responses in mice immunized with the vaccine candidate.

    • Main Results:

    • The engineered HIV is replication-defective, undergoing only one round of replication.
    • The VSV-G pseudotyped HIV can infect a broad range of cell types.
    • Immunization with the VSV-G-pseudotyped replication-defective HIV successfully elicited detectable antibody immune responses in mice.

    Conclusions:

    • A replication-defective, VSV-G pseudotyped HIV vaccine candidate offers a potentially safer alternative to live attenuated vaccines.
    • This approach maintains immunogenicity, demonstrated by antibody production in preclinical models.
    • Further research is warranted for advancing this vaccine strategy towards human clinical trials.